Jake P Mann1, Rita De Vito2, Antonella Mosca3, Anna Alisi4, Matthew J Armstrong5, Massimiliano Raponi6, Ulrich Baumann7, Valerio Nobili3,4. 1. Department of Paediatrics, University of Cambridge, Cambridge, UK. 2. Histopathology Unit, Bambino Gesu Hospital, IRCCS, Rome, Italy. 3. Hepatometabolic Unit, Bambino Gesu Hospital, IRCCS, Rome, Italy. 4. Liver Research Unit, Bambino Gesu Hospital, IRCCS, Rome, Italy. 5. National Institute for Health Research, Birmingham Liver Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK. 6. Medical Directorate, Bambino Gesu Hospital, IRCCS, Rome, Italy. 7. Paediatric Gastroenterology and Hepatology, Children's Hospital, Hannover Medical School, Hannover, Germany.
Abstract
UNLABELLED: Pediatric nonalcoholic fatty liver disease (NAFLD) histology demonstrates variable amounts of portal inflammation, which may be associated with more severe liver disease and fibrosis. We assessed the relationship between portal inflammation, hepatic fibrosis, and the metabolic syndrome in pediatric NAFLD. Children with biopsy-proven NAFLD were eligible for inclusion. Histology was assessed using Kleiner fibrosis stage and the Nonalcoholic Steatohepatitis Clinical Research Network system for portal inflammation. Patients were divided by histology into type 1, type 2, and overlap NAFLD. Multivariable ordinal logistic regression was used to determine factors associated with fibrosis and portal inflammation. The 430 Caucasian children were divided into 52 with type 1, 95 with type 2, and 283 with overlap NAFLD. Those with type 2 had a more severe metabolic phenotype, with higher body mass index z score (2.0 versus 1.6, P < 0.0001), waist circumference centile (96th versus 90th, P < 0.0001), and triglycerides (84 versus 77 mg/dL, P = 0.01) and lower high-density lipoprotein (46 versus 60 mg/dL, P = 0.004) than those with type 1. Similarly, those with overlap NAFLD had a more severe phenotype. Stage 2-3 fibrosis was present in 69/283 (24%) with overlap NAFLD. Portal inflammation was associated with stage 2-3 fibrosis on multivariable analysis (95% confidence interval 1.4-5.2, odds ratio = 3.7). Waist circumference centile was associated with portal inflammation (95% confidence interval 1.2-3.4, odds ratio = 2.0). CONCLUSION: Portal inflammation is associated with more advanced pediatric NAFLD and features of the metabolic syndrome.
UNLABELLED: Pediatric nonalcoholic fatty liver disease (NAFLD) histology demonstrates variable amounts of portal inflammation, which may be associated with more severe liver disease and fibrosis. We assessed the relationship between portal inflammation, hepatic fibrosis, and the metabolic syndrome in pediatric NAFLD. Children with biopsy-proven NAFLD were eligible for inclusion. Histology was assessed using Kleiner fibrosis stage and the Nonalcoholic Steatohepatitis Clinical Research Network system for portal inflammation. Patients were divided by histology into type 1, type 2, and overlap NAFLD. Multivariable ordinal logistic regression was used to determine factors associated with fibrosis and portal inflammation. The 430 Caucasian children were divided into 52 with type 1, 95 with type 2, and 283 with overlap NAFLD. Those with type 2 had a more severe metabolic phenotype, with higher body mass index z score (2.0 versus 1.6, P < 0.0001), waist circumference centile (96th versus 90th, P < 0.0001), and triglycerides (84 versus 77 mg/dL, P = 0.01) and lower high-density lipoprotein (46 versus 60 mg/dL, P = 0.004) than those with type 1. Similarly, those with overlap NAFLD had a more severe phenotype. Stage 2-3 fibrosis was present in 69/283 (24%) with overlap NAFLD. Portal inflammation was associated with stage 2-3 fibrosis on multivariable analysis (95% confidence interval 1.4-5.2, odds ratio = 3.7). Waist circumference centile was associated with portal inflammation (95% confidence interval 1.2-3.4, odds ratio = 2.0). CONCLUSION: Portal inflammation is associated with more advanced pediatric NAFLD and features of the metabolic syndrome.
Authors: Miriam B Vos; Lara Dimick-Santos; Ruby Mehta; Stephanie O Omokaro; Johannes Taminiau; Elmer Schabel; David E Kleiner; Peter Szitanyi; Piotr Socha; Jeffrey B Schwimmer; Stephanie Noviello; Debra G Silberg; Richard Torstenson; Veronica Miller; Joel E Lavine Journal: Gastroenterology Date: 2019-09-12 Impact factor: 22.682
Authors: Nikos Stratakis; Lucy Golden-Mason; Katerina Margetaki; Yinqi Zhao; Damaskini Valvi; Erika Garcia; Léa Maitre; Sandra Andrusaityte; Xavier Basagana; Eva Borràs; Mariona Bustamante; Maribel Casas; Serena Fossati; Regina Grazuleviciene; Line Småstuen Haug; Barbara Heude; Rosemary R C McEachan; Helle Margrete Meltzer; Eleni Papadopoulou; Theano Roumeliotaki; Oliver Robinson; Eduard Sabidó; Jose Urquiza; Marina Vafeiadi; Nerea Varo; John Wright; Miriam B Vos; Howard Hu; Martine Vrijheid; Kiros T Berhane; David V Conti; Rob McConnell; Hugo R Rosen; Lida Chatzi Journal: Hepatology Date: 2021-08-30 Impact factor: 17.298
Authors: Roberta Forlano; Benjamin H Mullish; Nikolaos Giannakeas; James B Maurice; Napat Angkathunyakul; Josephine Lloyd; Alexandros T Tzallas; Markos Tsipouras; Michael Yee; Mark R Thursz; Robert D Goldin; Pinelopi Manousou Journal: Clin Gastroenterol Hepatol Date: 2019-12-27 Impact factor: 11.382
Authors: Taylor K Soderborg; Sarah E Clark; Christopher E Mulligan; Rachel C Janssen; Lyndsey Babcock; Diana Ir; Bridget Young; Nancy Krebs; Dominick J Lemas; Linda K Johnson; Tiffany Weir; Laurel L Lenz; Daniel N Frank; Teri L Hernandez; Kristine A Kuhn; Angelo D'Alessandro; Linda A Barbour; Karim C El Kasmi; Jacob E Friedman Journal: Nat Commun Date: 2018-10-26 Impact factor: 14.919